Skip to main content
Erschienen in: Supportive Care in Cancer 1/2021

03.05.2020 | Original Article

Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors

verfasst von: Elizabeth S. Ver Hoeve, Leila Ali-Akbarian, Sarah N. Price, Nurhyikmah M. Lothfi, Heidi A. Hamann

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Fighting cancer is a costly battle, and understanding the relationship between patient-reported financial toxicity (FT) and health outcomes can help inform interventions for post-treatment cancer survivors.

Methods

Stages I–III solid tumor, insured US cancer survivors (N = 103) completed a survey addressing FT (as measured by the standardized COST measure) and clinically relevant health outcomes (including health-related quality of life [HRQOL] and adherence to recommended survivorship health behaviors). Univariate and multivariate analyses were used to assess demographic and disease-specific correlates of FT, and to assess the predictive value of FT on HRQOL and adherence to survivorship health behaviors.

Results

Approximately 18% of respondents noted FT levels associated with significant financial burden. In univariate analyses, after correcting for multiple comparisons, greater FT was associated with unpartnered status, non-retirement, and lower level of educational attainment. Greater FT was also significantly associated with HRQOL components of anxiety, fatigue, pain, physical functioning, and social functioning. FT was not significantly associated with any measured survivorship health behaviors. In multivariate analyses, FT was found to be a meaningful predictor of patient-reported anxiety, fatigue, physical functioning, and social functioning above and beyond theoretically and statistically relevant demographic characteristics.

Conclusions

Although overall levels of FT were lower among cancer survivors in this sample, as compared with active treatment patients assessed in previous studies, financial burden continued to be a concern for a significant minority of cancer survivors and was associated with components of reduced HRQOL. Further research is needed to understand FT among underinsured survivors and those treated in community oncology settings.

Implications for cancer survivors

Incorporation of FT assessment into survivorship care planning could enhance clinical assessment of survivors’ FT vulnerability, help address the dynamic and persistent challenges of survivorship, and help identify those most in need of intervention across the cancer care continuum.
Fußnoten
1
Survey data were stored in REDCap (Research Electronic Data Capture) and securely hosted on HIPAA-compliant servers.
 
2
The NCCN recommendation for alcohol consumption was not fully consistent with the dichotomization of the study’s alcohol question because the study question asked for alcohol consumption > or < 5 drinks per week and the NCCN recommendation for alcohol consumption is ‘no more than 1 drink per day for women and 2 drinks per day for men’.
 
Literatur
2.
Zurück zum Zitat National Cancer Institute. Financial toxicity (financial distress) and cancer treatment (PDQ®): patient version. Natl. Cancer Inst. 2017 National Cancer Institute. Financial toxicity (financial distress) and cancer treatment (PDQ®): patient version. Natl. Cancer Inst. 2017
3.
Zurück zum Zitat Gilligan AM, Alberts DS, Roe DJ, Skrepnek GH (2018) Death or bebt? National estimates of financial toxicity in persons with newly-diagnosed cancer. Am J Med. Elsevier 131:1187–1199.e5 Gilligan AM, Alberts DS, Roe DJ, Skrepnek GH (2018) Death or bebt? National estimates of financial toxicity in persons with newly-diagnosed cancer. Am J Med. Elsevier 131:1187–1199.e5
4.
Zurück zum Zitat Gordon LG, Merollini KMD, Lowe A, Chan RJ (2017) A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient - Patient-Centered Outcomes Res 10:295–309CrossRef Gordon LG, Merollini KMD, Lowe A, Chan RJ (2017) A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient - Patient-Centered Outcomes Res 10:295–309CrossRef
5.
Zurück zum Zitat Zafar SY, Abernethy AP (2013) Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park). NIH Public Access 27(80):1–149 Zafar SY, Abernethy AP (2013) Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park). NIH Public Access 27(80):1–149
6.
Zurück zum Zitat Narang AK, Nicholas LH (2017) Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer. JAMA Oncol American Medical Association 3:757–765CrossRef Narang AK, Nicholas LH (2017) Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer. JAMA Oncol American Medical Association 3:757–765CrossRef
7.
Zurück zum Zitat Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al (2013) Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). NIH Public Access 32:1143–52 Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al (2013) Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). NIH Public Access 32:1143–52
8.
Zurück zum Zitat Jones SM, Yi JC, Jim HS, Loren AW, Majhail NS, Uberti J, Whalen V, Leisenring WM, Flowers MED, Lee SJ, Syrjala KL (2020) Age and gender differences in financial distress among hematopoietic cell transplant survivors. Support Care Cancer:1–11. https://doi.org/10.1007/s00520-019-05291-1 Jones SM, Yi JC, Jim HS, Loren AW, Majhail NS, Uberti J, Whalen V, Leisenring WM, Flowers MED, Lee SJ, Syrjala KL (2020) Age and gender differences in financial distress among hematopoietic cell transplant survivors. Support Care Cancer:1–11. https://​doi.​org/​10.​1007/​s00520-019-05291-1
9.
Zurück zum Zitat Yabroff KR, Dowling EC, Guy GP, Banegas MP, Davidoff A, Han X et al (2016) Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol 34:259–267CrossRefPubMed Yabroff KR, Dowling EC, Guy GP, Banegas MP, Davidoff A, Han X et al (2016) Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol 34:259–267CrossRefPubMed
10.
Zurück zum Zitat Tran G, Zafar SY (2018) Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 6:166–166CrossRefPubMedPubMedCentral Tran G, Zafar SY (2018) Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 6:166–166CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat National Cancer Institute: Division of Cancer Control and Population Sciences (2019) Financial Burden of Cancer Care National Cancer Institute: Division of Cancer Control and Population Sciences (2019) Financial Burden of Cancer Care
12.
Zurück zum Zitat Park J, Look KA (2019) Health care expenditure burden of cancer care in the United States. Inq (United States) 56 Park J, Look KA (2019) Health care expenditure burden of cancer care in the United States. Inq (United States) 56
13.
Zurück zum Zitat Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, Winkler EC (2019) Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol 30:1061–1070CrossRefPubMedPubMedCentral Witte J, Mehlis K, Surmann B, Lingnau R, Damm O, Greiner W, Winkler EC (2019) Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol 30:1061–1070CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, Leighl NB (2019) Financial burden among patients with lung cancer in a Publically funded health care system. Clin lung cancer 20(4):231–236 Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, Leighl NB (2019) Financial burden among patients with lung cancer in a Publically funded health care system. Clin lung cancer 20(4):231–236
15.
Zurück zum Zitat de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 120:3245–3253CrossRefPubMed de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 120:3245–3253CrossRefPubMed
16.
Zurück zum Zitat de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, Nicholas LH, O’Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 123:476–484CrossRefPubMed de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, Nicholas LH, O’Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 123:476–484CrossRefPubMed
17.
Zurück zum Zitat Honda K, Gyawali B, Ando M, Sugiyama K, Mitani S, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K (2018) A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. Ecancermedicalscience 12:847 Honda K, Gyawali B, Ando M, Sugiyama K, Mitani S, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K (2018) A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. Ecancermedicalscience 12:847
18.
Zurück zum Zitat Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA (2015) Stadtmauer EA Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2:e408–e416 Huntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA (2015) Stadtmauer EA Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2:e408–e416
19.
Zurück zum Zitat Rosenzweig M, West M, Matthews J, Stokan M, Yoojin Kook YK, Gallups S et al (2019) Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum 46:83–91CrossRefPubMed Rosenzweig M, West M, Matthews J, Stokan M, Yoojin Kook YK, Gallups S et al (2019) Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum 46:83–91CrossRefPubMed
20.
Zurück zum Zitat Allcott N, Dunham L, Levy D, Carr J, Stitzenberg K (2019) Financial burden amongst cancer patients treated with curative intent surgery alone. Am J Surg 218:452–456CrossRefPubMedPubMedCentral Allcott N, Dunham L, Levy D, Carr J, Stitzenberg K (2019) Financial burden amongst cancer patients treated with curative intent surgery alone. Am J Surg 218:452–456CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR (2017) Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 109:djw205 Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR (2017) Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 109:djw205
23.
Zurück zum Zitat Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al (2007) The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care pp. S3–S11 Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al (2007) The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care pp. S3–S11
24.
Zurück zum Zitat Gershon RC, Rothrock N, Hanrahan R, Bass M, Cella D (2010) The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas 11:304–314PubMedPubMedCentral Gershon RC, Rothrock N, Hanrahan R, Bass M, Cella D (2010) The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas 11:304–314PubMedPubMedCentral
25.
Zurück zum Zitat PROMIS Cooperative Group (2013) PROMIS® instrument development and validation scientific standards version 2.0. 0:1–72 PROMIS Cooperative Group (2013) PROMIS® instrument development and validation scientific standards version 2.0. 0:1–72
27.
Zurück zum Zitat National Comprehensive Cancer Network I (2012) NCCN guidelines: survivorship. Am J Clin Pathol 137:516–542CrossRef National Comprehensive Cancer Network I (2012) NCCN guidelines: survivorship. Am J Clin Pathol 137:516–542CrossRef
28.
Zurück zum Zitat Scott Baker K, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, et al (2019). NCCN Guidelines Panel Disclosures Continue NCCN Guidelines Version 2.2019 Survivorship Scott Baker K, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, et al (2019). NCCN Guidelines Panel Disclosures Continue NCCN Guidelines Version 2.2019 Survivorship
30.
Zurück zum Zitat Holm S (1978) Board of the Foundation of the Scandinavian Journal of Statistics A simple sequentially rejective multiple test procedure author ( s ): Sture Holm Published by : Wiley on behalf of Board of the Foundation of the Scandinavian Journal of Statistics Stable U. Scand J Stat 6:65–70 Holm S (1978) Board of the Foundation of the Scandinavian Journal of Statistics A simple sequentially rejective multiple test procedure author ( s ): Sture Holm Published by : Wiley on behalf of Board of the Foundation of the Scandinavian Journal of Statistics Stable U. Scand J Stat 6:65–70
31.
Zurück zum Zitat Stanton AL, Rowland JH, Ganz PA (2015) Life after diagnosis and treatment of cancer in adulthood: contributions from psychosocial oncology research. Am Psychol 70:159–174CrossRefPubMed Stanton AL, Rowland JH, Ganz PA (2015) Life after diagnosis and treatment of cancer in adulthood: contributions from psychosocial oncology research. Am Psychol 70:159–174CrossRefPubMed
32.
Zurück zum Zitat Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E (2010) Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health American Public Health Association 100(Suppl 1):S186–S196CrossRef Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E (2010) Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health American Public Health Association 100(Suppl 1):S186–S196CrossRef
34.
Zurück zum Zitat Lehto RH (2017) Psychosocial challenges for patients with advanced lung cancer: interventions to improve well-being. Lung Cancer Targets Ther 8:79–90CrossRef Lehto RH (2017) Psychosocial challenges for patients with advanced lung cancer: interventions to improve well-being. Lung Cancer Targets Ther 8:79–90CrossRef
35.
Zurück zum Zitat Hamann HA, Ostroff JS, Marks EG, Gerber DE, Schiller JH, Lee SJC (2014) Stigma among patients with lung cancer: a patient-reported measurement model. Psychooncology. 23:81–92CrossRefPubMed Hamann HA, Ostroff JS, Marks EG, Gerber DE, Schiller JH, Lee SJC (2014) Stigma among patients with lung cancer: a patient-reported measurement model. Psychooncology. 23:81–92CrossRefPubMed
36.
Zurück zum Zitat Sriram N, Mills J, Lang E, Dickson HK, Hamann HA, Nosek BA, et al (2015) Attitudes and stereotypes in lung cancer versus breast cancer. Gorlova OY, editor. PLoS One 10:e0145715 Sriram N, Mills J, Lang E, Dickson HK, Hamann HA, Nosek BA, et al (2015) Attitudes and stereotypes in lung cancer versus breast cancer. Gorlova OY, editor. PLoS One 10:e0145715
37.
Zurück zum Zitat Coughlin SS, Dean LT (2019) Cancer survivorship care plans, financial toxicity, and financial planning alleviating financial distress among cancer survivors. Support Care Cancer 27:1969–1971CrossRefPubMedPubMedCentral Coughlin SS, Dean LT (2019) Cancer survivorship care plans, financial toxicity, and financial planning alleviating financial distress among cancer survivors. Support Care Cancer 27:1969–1971CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Zafar SY, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB (2017) How should we intervene on the financial toxicity of cancer care? One shot, four perspectives. Am Soc Clin Oncol Educ B 37:35–39CrossRef Zafar SY, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB (2017) How should we intervene on the financial toxicity of cancer care? One shot, four perspectives. Am Soc Clin Oncol Educ B 37:35–39CrossRef
40.
Zurück zum Zitat Sweet E, Nandi A, Adam EK, McDade TW (2013) The high price of debt: household financial debt and its impact on mental and physical health. Soc Sci Med NIH Public Access 91:94–100 Sweet E, Nandi A, Adam EK, McDade TW (2013) The high price of debt: household financial debt and its impact on mental and physical health. Soc Sci Med NIH Public Access 91:94–100
41.
Zurück zum Zitat Drentea P, Lavrakas PJ (2000) Over the limit: the association among health, race and debt. Soc Sci Med Pergamon 50:517–529CrossRef Drentea P, Lavrakas PJ (2000) Over the limit: the association among health, race and debt. Soc Sci Med Pergamon 50:517–529CrossRef
42.
Zurück zum Zitat Rodriguez JL, Hawkins NA, Berkowitz Z, Li C (2015) Factors associated with health-related quality of life among colorectal cancer survivors. Am J Prev med. NIH Public Access 49:S518–27 Rodriguez JL, Hawkins NA, Berkowitz Z, Li C (2015) Factors associated with health-related quality of life among colorectal cancer survivors. Am J Prev med. NIH Public Access 49:S518–27
43.
Zurück zum Zitat Yousuf ZS (2016) Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst 108:djv370CrossRef Yousuf ZS (2016) Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst 108:djv370CrossRef
45.
Zurück zum Zitat Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, Ramsey S, Schwartz N, Kreizenbeck K, Nelson J, Balch A, Singleton E, Gallagher K, Overstreet K (2018) Pilot feasibility study of an oncology financial navigation program. J Oncol Pract 14:e122–e129CrossRefPubMed Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, Ramsey S, Schwartz N, Kreizenbeck K, Nelson J, Balch A, Singleton E, Gallagher K, Overstreet K (2018) Pilot feasibility study of an oncology financial navigation program. J Oncol Pract 14:e122–e129CrossRefPubMed
46.
Zurück zum Zitat Sedrak MS, Myers JS, Small DS, Nachamkin I, Ziemba JB, Murray D, Kurtzman GW, Zhu J, Wang W, Mincarelli D, Danoski D, Wells BP, Berns JS, Brennan PJ, Hanson CW, Dine CJ, Patel MS (2017) Effect of a price transparency intervention in the electronic health record on clinician ordering of inpatient laboratory tests. JAMA Intern Med 177:939–945CrossRefPubMedPubMedCentral Sedrak MS, Myers JS, Small DS, Nachamkin I, Ziemba JB, Murray D, Kurtzman GW, Zhu J, Wang W, Mincarelli D, Danoski D, Wells BP, Berns JS, Brennan PJ, Hanson CW, Dine CJ, Patel MS (2017) Effect of a price transparency intervention in the electronic health record on clinician ordering of inpatient laboratory tests. JAMA Intern Med 177:939–945CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Kline RM, Bazell C, Smith E, Schumacher H, Rajkumar R, Conway PH (2015) Centers for Medicare and Medicaid Services: using an episode-based payment model to improve oncology care. J Oncol Pract 11:114–116CrossRefPubMed Kline RM, Bazell C, Smith E, Schumacher H, Rajkumar R, Conway PH (2015) Centers for Medicare and Medicaid Services: using an episode-based payment model to improve oncology care. J Oncol Pract 11:114–116CrossRefPubMed
48.
Zurück zum Zitat Nipp RD, Lee H, Gorton E, Lichtenstein M, Kuchukhidze S, Park E, et al (2019) Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention. Oncologist. AlphaMed Press theoncologist.2019–0146 Nipp RD, Lee H, Gorton E, Lichtenstein M, Kuchukhidze S, Park E, et al (2019) Addressing the financial burden of cancer clinical trial participation: longitudinal effects of an equity intervention. Oncologist. AlphaMed Press theoncologist.2019–0146
49.
Zurück zum Zitat PDQ Adult Treatment Editorial Board PATE (2002) Financial toxicity (financial distress) and cancer treatment (PDQ®): patient version. PDQ Cancer Inf. Summ. National Cancer Institute (US) PDQ Adult Treatment Editorial Board PATE (2002) Financial toxicity (financial distress) and cancer treatment (PDQ®): patient version. PDQ Cancer Inf. Summ. National Cancer Institute (US)
50.
Zurück zum Zitat Carpentier MY, Tiro JA, Savas LS, Kay L, Melhado T V, Coan SP, et al (2014) A feasibility study 7:155–63 Carpentier MY, Tiro JA, Savas LS, Kay L, Melhado T V, Coan SP, et al (2014) A feasibility study 7:155–63
51.
Zurück zum Zitat Millar MM, Kinney AY, Camp NJ, Cannon-Albright LA, Hashibe M, Penson DF, Kirchhoff AC, Neklason DW, Gilsenan AW, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME (2019) Sweeney C Predictors of response outcomes for research recruitment through a central cancer registry: evidence from 17 recruitment efforts for population-based studies. Am J Epidemiol 188:928–939 Millar MM, Kinney AY, Camp NJ, Cannon-Albright LA, Hashibe M, Penson DF, Kirchhoff AC, Neklason DW, Gilsenan AW, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME (2019) Sweeney C Predictors of response outcomes for research recruitment through a central cancer registry: evidence from 17 recruitment efforts for population-based studies. Am J Epidemiol 188:928–939
52.
Zurück zum Zitat Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240 Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240
Metadaten
Titel
Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors
verfasst von
Elizabeth S. Ver Hoeve
Leila Ali-Akbarian
Sarah N. Price
Nurhyikmah M. Lothfi
Heidi A. Hamann
Publikationsdatum
03.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2021
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05468-z

Weitere Artikel der Ausgabe 1/2021

Supportive Care in Cancer 1/2021 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.